At the forefront of Immuno-Oncology With T-Cell Therapeutics OTCMKTS: TPIV.

Transcription

1 At the forefront of Immuno-Oncology With T-Cell Therapeutics OTCMKTS:

2 CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.

3 TapImmune: A Phase 2 Immuno-Oncology Company TapImmune is a Phase 2 Clinical Stage T-Cell immuno-oncology company in an immunotherapy market that will be the leading treatment for cancer, with sales of over $41 billion in 2020* Collaborations and independent vetting of s technology by Astra Zeneca, Memorial Sloan Kettering, Mayo Clinic and the US Department of Defense (DOD). Four Phase 2 studies will be up and enrolling by the end of 2016 in ovarian and triple negative breast cancer. With Fastrack designation and Orphan drug status for ovarian cancer. Second product IND to be filed by year-end with Phase 2 studies starting in * 3

4 TapImmune Opportunity Immune-based off-the-shelf platform therapy for cancer AND metastatic disease Phase 1 human studies successfully completed in two trials with two distinct products in collaboration with the prestigious Mayo Clinic High potential to use in combination with existing and developmental immuno-therapies. Unusually low market cap. 4

5 How s Approach to T-cell Vaccines Works Excellent targets (FRA;HER2neu) expressed on surface of majority of tumor target cells Selection of Antigens from immune responses in patients Choice of small peptide antigens that will not induce T- regulatory cells Selection of Class II antigens that can broadly stimulate T- helper cells, T-killer cells and T-memory cells Selection of antigens to cover ~85% of HLA (DR) genotypes broad population coverage Robust T-cell responses in over 90% patients treated 5

6 J Clin Invest. 2015;125(9):

7 Lead Product: 200 Folate Receptor Alpha for: - Triple Negative Breast Cancer - Ovarian Cancer - Non-Small Cell Lung Cancer (NSCLC) Phase 2 studies starting in 2016 with: 7

8 200 Lead Product Folate Receptor Alpha Product

9 B cells Antibodies Signaling ADCC Complement 200 Peptide Vaccines Stimulate the Adaptive Immune System: CD4 helper T cells (Class II peptides) Inflammation (macrophages and neutrophils) Antibodies Induce/Enhance cytotoxic T cells CD8 cytolytic T cells (Class I peptides) Tumor lysis

10 200 Vaccine Composition Targets Folate Receptor Alpha (breast and ovarian cancer) Five Class II peptides (antigens) Four T cell epitopes and one antibody epitope Spontaneous immunity to peptides in cancer patients FR76 FR30 FR56 FR113 FR238 FR76 FR238

11 200 Ovarian/Breast Cancer Folate receptor alpha antigens from Mayo Clinic Folate receptor alpha is overexpressed in ~ 90% ovarian cancer cells and over 80% of triple negative breast cancer and 80% NSCLC In US, approximately 30,000 ovarian cancer and 40,000 triple negative breast cancer patients newly diagnosed every year Only treatment options are surgery, radiation and chemotherapy Time to recurrence is relatively short for these cancers and survival prognosis is extremely poor after recurrence 11

12 200 - Results From Phase 1 Ovarian/Breast Cancer Trial Phase 1 study conducted at Mayo Clinic showed 200 was generally welltolerated & safe Immune responses in 20 of 21 evaluable patients in final analysis 16 out of 16 patients demonstrated T-cell responses lasting into the observation phase Data published in Journal of Clinical Oncology at ASCO in Chicago May

13 200 Clinical Development Plan in Next 12 Months

14 200 Clinical Program -4 Phase 2 trials enrolling by the end of 2016 Sponsor: IND Holder Collaborators Status N Indication Study Design Mayo Clinic (MC1015) TapImmune Completed 22 Breast and Ovarian Cancer Phase I Safety & Immune Responses Tapimmune (FRV-002*) Multiple Sites Recruiting 80 TNBC Phase II Dose & Boost Safety & Immune Responses Sloan Kettering Cancer Center (FRV-003**) AstraZeneca TapImmune Recruiting 40 Platinum resistant ovarian Phase II Combination with durvalumab Time to disease progression Mayo Clinic TapImmune Planned 2016 start 280 TNBC Phase II Time to disease progression Tapimmune (FRV-004) Multiple Sites Planned 2016 start 80 Platinum sensitive ovarian * clinicaltrials.gov/ct2/show/nct ?term=tapimmune&rank=2 **clinicaltrials.gov/ct2/show/nct ?term=ovarian+and+jason+konn er&rank=1 Phase II Time to disease progression

15 110 HER2/NEU Breast Cancer Product

16 Her2/neu Breast Cancer ( 100/110) HER2/neu antigens from Mayo Clinic Applicable to breast, ovarian and colorectal cancer HER2/neu is overexpressed in ~ 30% breast cancer patients (total 220,000 /yr) Roche s monoclonal antibodies (Herceptin & Parjeta ) can only treat ~ 20% of HER2/neu + ve patients (+$6 billion sales in 2013) 110 (Type 1 antigen) more effective at killing breast cancer cells in culture than NeuVax Type 1 antigen (J Immunol : ) 16

17 Results from Phase 1 Her2/neu Breast Cancer Trial 100 Phase 1 study conducted at Mayo Clinic 100 was welltolerated and safe 4 HER2/neu Class II antigens (p59, p88, p422, and p885) 22 Patients with Her2/neu+ve breast cancer (Stage II-III) received standard treatment and were disease free 19 out of 20 patients showed robust T-cell responses to two antigens (p 59; p88); 15 out of 20 patients responded to all four antigens Data presented at 2015 San Antonio Breast Cancer Symposium, Dec

18 100/110 - Clinical Development Plan in Next 12 Months Complete manufacturing and CMC work for Clinical Development Pre-IND meeting with FDA File IND with FDA Initiate Phase 2 study(ies) 18

19 110 clinical program IND to be filed by 1Q 2017 GMP Drug formulation is in Process Sponsor: IND Holder Mayo Clinic* Tapimmune (FRV-005) Collaborat ors Status N Indication Study Design TapImmune Completed 22 HER2neu Breast Cancer Mayo Clinic & Multiple sites Planned 2017 start 80 DCIS Phase II 100 Phase I Safety & Immune Responses * clinicaltrials.gov/ct2/show/nct ?term=mayo+and+amy+degnim&r ank=1

20 Why TapImmune s HER2neu Breast Cancer Vaccine Is Different and Potentially Better Than NeuVax 110 (TapImmune) Class I antigen (p ) Stimulates CD8 T-cells Order of magnitude stronger binding to HLA-A2 4 x more effective at killing human breast cancer cells in culture Naturally processed by cells Peer reviewed scientific comparison E75 and p J.Immunol. (2013) 190, Class II antigens (p59, p88, p422, and p885) Stimulates CD4 T-cells Phase I - robust immune responses in over 90% patients treated More comprehensive stimulation of T-helper and T-killer cells Neuvax (Galena) Class I antigen (E75) Stimulates CD8 T-cells Order of magnitude lower binding to HLA- A2 4x less effective at killing human breast cancer cells in culture Not naturally processed by cells NO Class II Antigens = No Helper T- cell assistance Failed Phase II & Phase III clinical endpoints 20

21 PolyStart TM High Potential Preclinical Technology PolyStart technology for increasing the immune response recently received a patent allowance Homegrown technology (TapImmune is the inventor) no royalties; all fields of use available Preclinical but could be added to cancer trials in the near future High potential to out-license for uses outside of TapImmune s fields of interest- potential revenue stream Recent patent approvals 21

22 Update on Clinical & Regulatory Milestones 200 Phase 2 trials begin enrollment Recruitment started Patient treatment has begun 200 Combination study (with Astra Zeneca and Sloan Kettering) in Ovarian Cancer begins enrollment Patient recruitment 2 nd Q 2016 = has begun 200 DOD/Mayo trial to begin enrollment 3 nd Q Phase 2 study in platinum sensitive ovarian cancer patients (Fast Track designation) IND submission in 4 th Q

23 Management Glynn Wilson, Ph.D. Chairman & CEO Founder and responsible for the development of a preclinical and clinical product pipeline and in licensing vaccine technologies from the Mayo Clinic. Glynn brings an extensive background of success in corporate management and product development with tenures in both major multinational pharmaceutical companies and start-up pharmaceutical/biotech organizations including development of $billion products. Former positions include Worldwide Head of Drug Delivery at SmithKline Beecham Pharmaceuticals and Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals where he was responsible for creating R&D strategies for emerging biological products.. Glynn has a Ph.D. in Biochemistry from Heriot-Watt University, Edinburgh and conducted medical research at Rockefeller University. John N. Bonfiglio, Ph.D., MBA President & Chief Operating Officer Dr. John N. Bonfiglio has over 30 years experience in the pharmaceutical/biotechnology business. Dr. Bonfiglio started his career with Allergan pharmaceuticals as a scientist and moved into project management, strategic marketing and business development. Two of his projects while at Allergan are now marketed products- Tazarotene and AlphaGan. He spent 3 years at Baxter HealthCare before starting a career in small biotech companies. He rose to the position of CEO at Peregrine Pharmaceuticals where he turned around the struggling and financially strapped company by reducing the burn rate, licensing technologies and raising capital in the public markets. He also was COO at Cypress Biosciences, CEO of the Immune Response Corporation and CEO at Argos Therapeutics Finally, most recently he completed a successful stint at Oragenics in Tampa, Fl. Here he completed two strategic deals with Intrexon Corporation, raised $29M in three financings under very favorable terms, relisted the company on the NYSE:MKT. 23

24 Management Patrick Yeramian, MD Consultant Medical Director 25 years experience in clinical development of new drugs, biopharmaceuticals and vaccines including approval of 5 products and over 20 successful IND and CTX/CTA approvals. Former positions include Director Clinical Research, Fornier Group, Research Clinical Director, Europe, Delalande Group, Director Clinical Research, G.D. Searle, and Vice-President Medical and Regulatory Affairs at Viragen. He has a medical degree from the University of Paris XII and was a Medical Resident and Research Fellow in Virology at the E. Percy Military Hospital, Paris. Robert Florkiewicz, Ph.D Head of Research Molecular Cell Biologist with over 25 years experience in Biotech and Academia. At Synergen, Inc. he helped establish the viral vector and animal cell expression group. He was the Director of Cellular and Molecular Biology and co-founder of Ciblex Corporation, a spin-out from his laboratory at the Scripps Institute, San Diego. He was a patent agent at Seed Intellectual Law Group in Seattle and at ID Biomedical where he managed the Company s intellectual property portfolio prior to and through its acquisition by GSK. He is the inventor of TapImmune s PolyStart technology. 24

25 Phase 2 Team Advisors Keith Knutson, Ph.D. Director, Immunotherapy and Cancer Vaccine Program, Mayo Clinic, Jacksonville., FL. Discoverer of HER2/neu and FRA peptide antigens in clinical trials Edith A. Perez, MD Deputy director at large for Mayo Clinic Cancer Center in Jacksonville, Fla., and Professor at Mayo Clinic College of Medicine. Chair of the Mayo Clinic Breast Cancer Translational Genomics Program Mark Peagram, MD Director of the Breast Cancer Oncology Program at Stanford Women s Cancer Center and co-director of Stanford s Molecular Therapeutics Program 25

26 Equity Overview Capital Structure Shares Outstanding ~70 M Public Float ~36 M Market cap $35.5 M Stock Price $0.50 Volume (3m): ~325 K Cash Balance: $~5.7M as of 3/31/16 Financing Warrant exercise from 2015 financing for Phase 2 26

27 Why Invest in TapImmune now? Immunotherapy is the fastest growing pharmaceutical sector with large market opportunities Successful Phase 1 Clinical Trials Multiple Phase 2 Clinical Trial(s) for Triple Negative Breast Cancer and Ovarian starting 2016 Independent vetting of the technology by DOD, Astra Zeneca & Sloan Kettering Experienced management, clinical and advisory team Series of preclinical and clinical value inflexion points 27

28 CONTACT: GLYNN WILSON Chief Executive Officer JOHN BONFIGLIO Strategic Advisor and Board member OTCMKTS: 28